{"schema_version":"1.0","type":"article","title":"嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.md","lang":"zh-Hant","date":"2026-08-09","publish_at":"2026-08-09T08:00:00+08:00","updated_at":"2026-08-09","category":"商業分析系列","topic":"商業分析系列","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","乾癬","IL-23R","口服胜肽","新藥商業化"],"summary":"ICOTYDE 上市後第一個完整季度累積逾 18,000 張處方。口服 IL-23R 胜肽已取得進入高療效市場的資格，真正的商業答案仍取決於續方、支付品質、長期留存與多適應症。","key_points":[],"facts":[],"sections":["01｜每天一顆，嬌生怎麼把胜肽送進體內？","02｜18,000 張處方點火，付費品質還要驗收","03｜口服藥，終於拿出療效說服力","04｜每日一顆，真實世界留存才是答案","05｜50 億美元，要靠多適應症兌現","06｜先跑出一個產品，平台價值還要慢慢累積","07｜台灣讀者接下來看什麼？","最後一句","參考資料","免責聲明"],"references":[{"title":"[FDA ICOTYDE label]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf"},{"title":"[FDA multidisciplinary review]","source":"","date":"","url":"https://www.fda.gov/media/192646/download"},{"title":"[J&J FDA approval release]","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide"},{"title":"[J&J 2025 PASI 90 維持資料]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2025/Icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis/default.aspx"},{"title":"[J&J one-year results]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/ICOTYDE-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis/default.aspx"},{"title":"[J&J 2026 Q2 results]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx"},{"title":"[J&J 2026 Q2 earnings call transcript]","source":"","date":"","url":"https://s203.q4cdn.com/636242992/files/doc_financials/2026/q2/JNJ-USQ_Transcript_2026-07-15.pdf"},{"title":"[J&J development pipeline]","source":"","date":"","url":"https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx"}],"images":[{"alt":"ICOTYDE 進入口服高療效乾癬市場","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-01.png"},{"alt":"上市初期處方、病人、開方者與保險覆蓋，是需求訊號而非完整收入答案","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-02.png"},{"alt":"解讀 ICOTYDE 一年療效時，必須先看清楚分析分母","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-03.png"},{"alt":"ICOTYDE 商業化後續要看付費處方、續方留存、保險品質與長期結果","url":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-09）。嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？。https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-09-icotyde-oral-il23r-launch-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}